| pubmed-article:12716445 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C1565860 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C1705323 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C0549178 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C0034866 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C1548787 | lld:lifeskim |
| pubmed-article:12716445 | lifeskim:mentions | umls-concept:C0442821 | lld:lifeskim |
| pubmed-article:12716445 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:12716445 | pubmed:dateCreated | 2003-4-28 | lld:pubmed |
| pubmed-article:12716445 | pubmed:abstractText | Cyclooxygenase (COX)-2 selective inhibitors have been shown to have comparable efficacy to nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Large outcome studies have shown that patients with OA and RA not taking low-dose aspirin have fewer symptomatic and complicated upper GI events when treated with COX-2 selective inhibitors than with nonselective NSAIDs. When used in recommended dosages, there is no convincing evidence that patients treated with COX-2 selective inhibitors have an increased incidence of cardiovascular thrombotic events, including non-fatal myocardial infarction, than patients treated with either placebo or nonselective NSAIDs other than naproxen. Co-therapy with low-dose aspirin is recommended in patients with OA and RA at increased risk for cardiovascular events; the need for gastroprotective therapy in such patients is controversial. | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12716445 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12716445 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12716445 | pubmed:issn | 1478-6362 | lld:pubmed |
| pubmed-article:12716445 | pubmed:author | pubmed-author:HochbergMarc... | lld:pubmed |
| pubmed-article:12716445 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:12716445 | pubmed:volume | 5 | lld:pubmed |
| pubmed-article:12716445 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12716445 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12716445 | pubmed:pagination | 28-31 | lld:pubmed |
| pubmed-article:12716445 | pubmed:dateRevised | 2010-7-21 | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:meshHeading | pubmed-meshheading:12716445... | lld:pubmed |
| pubmed-article:12716445 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12716445 | pubmed:articleTitle | COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients. | lld:pubmed |
| pubmed-article:12716445 | pubmed:affiliation | Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, Maryland, USA. mhochber@umaryland.edu | lld:pubmed |
| pubmed-article:12716445 | pubmed:publicationType | Editorial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12716445 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12716445 | lld:pubmed |
